21618-92-8

Usage

Furanone ring structure

The compound has a five-membered furanone ring, which is a key structural feature.

Side chain with a dihydroxyphenyl group

The compound has a side chain that includes a dihydroxyphenyl group, which may contribute to its biological activity.

Natural occurrence

The compound is commonly found in natural sources such as fruits, vegetables, and other plant materials.

Biological activities

2(3H)-Furanone, 5-[(3,4-dihydroxyphenyl)methyl]dihydro-(9CI) has been studied for its potential antioxidant and antimicrobial properties.

Use in food and cosmetic products

The compound has been investigated for its potential use in food and cosmetic products due to its pleasant odor and flavor.

Versatile applications

2(3H)-Furanone, 5-[(3,4-dihydroxyphenyl)methyl]dihydro-(9CI) has potential applications in various industries, including food, cosmetics, and pharmaceuticals.

InChI:InChI=1/C11H12O4/c12-9-3-1-7(6-10(9)13)5-8-2-4-11(14)15-8/h1,3,6,8,12-13H,2,4-5H2

Upstream product

• 72719-14-3 5-(3,4-dimethoxybenzyl)dihydrofuran-2(3H)-one 
• 24243-80-9 δ‐(3‐methoxy‐4‐hydroxyphenyl)‐γ‐valerolactone 
• 39716-58-0 pent-4-enoyl chloride 
• 613-70-7 2-methoxyphenyl acetate 
• 2859-78-1 4-Bromoveratrole 
• 10353-53-4 1,2-epoxy-5-hexene 
• 848653-56-5 4-hydroxy-5-(3-hydroxy-4-methoxy-phenyl)-pentanoic acid 
• 90-05-1 2-methoxy-phenol 
• 183593-98-8 5-iodo-2-methoxyphenyl acetate 
• 591-80-0 pent-4-enoic acid 
• 818-57-5 Methyl 4-pentenoate 
• 848653-51-0 5-(3-hydroxy-4-methoxy-benzyl)-dihydro-furan-2-one 
• 848653-50-9 5-(3-acetoxy-4-methoxy-phenyl)-4-hydroxy-pentanoic acid methyl ester 

Downstream Products

• 72719-14-3 5-(3,4-dimethoxy-phenyl)-4-hydroxy-valeric acid-lactone 

Relevant academic research and scientific papers

Concise synthesis of catechin metabolites 5-(30,40-dihydroxyphenyl)-γ-valerolactones (dhpv) in optically pure form and their stereochemical effects on skin wrinkle-reducing activities

A concise and scalable synthetic route for optically pure (4S) and (4R)-5-(30,40-dihydroxyphenyl)-γ-valerolactones (DHPVs), catechin metabolites, has been developed via the efficient construction of a γ-valerolactone moiety from hexe

Novel method for synthesizing DHPV

The present invention relates to a novel synthesis method of DHPV. More specifically, the present invention relates to the novel synthesis method of (5-3andprime;,4andprime;-dihydroxyphenyl)-andgamma;-valerolactone (DHPV) which is a major metabolite of ca

COMPOSITION FOR PREVENTING, IMPROVING OR TREATING PHOTOAGING OF SKIN COMPRISING DHPV

The present invention relates to a photoaging inhibitor, and more specifically it relates to a pharmaceutical composition, a food composition or a cosmetic composition for preventing, improving or treating photoaging of skin, comprising DHPV (5-(3′,4′-Dih

Concise synthesis of ring-fission metabolites of epicatechin: 5-(3,4-dihydroxybenzyl)dihydrofuran-2(3H)-one M6

The ring-fission metabolites of epicatechin, 5-(3,4-dihydroxybenzyl) dihydrofuran-2(3H)-one M6 and 3-methylated M6, were prepared from 3,4-dihydroxybenzaldehyde and furan-2(5H)-one using two new concise methods in excellent yields (three or two steps in 4

Synthesis and biological activity of the tea catechin metabolites, M4 and M6 and their methoxy-derivatives

Syntheses are reported for metabolites M4 (1) and M6 (2) of the green tea polyphenols epicatechin (EC) and epigallocatechin (EGC) and their gallate derivatives. Several methoxy-derivatives of 1 and 2 were also prepared. Compounds 1 and 2 were evaluated for growth inhibitory activity against a panel of immortalized and malignant human cell lines with 1 being the more active compound. The possible antiinflammatory activity of 1 and its trimethoxy derivative was also evaluated. Neither compound inhibited the release of arachidonic acid, although 1 inhibited NO production by 50% at 20 μM.

Urinary metabolites of French maritime pine bark extract in humans

After oral administration of 5.28 g and 1.06 g of French maritime pine bark extract to a human volunteer, metabolites of some of the components of the extract could be detected. Ferulic acid and taxifolin, conjugated as glucuronide/sulphate, were excreted within 18 h. The peak urinary excretion was observed approximately 2-3 h after intake. Recovery of ferulic acid in urine was 36-43% and 7-8% for taxifolin. Two further metabolites could be identified as δ-(3,4-dihydroxy-phenyl)-γ-valerolactone and δ-(3-methoxy-4- hydroxyphenyl)-γ-valerolactone conjugated with glucuronic acid/sulphate. These metabolites could also be detected after intake of 960 mg of a procyanidin fraction of French maritime pine bark extract. Thus, it was shown that procyanidins are metabolised by humans. Both metabolites show maximal urinary excretion 8-12 h after intake and are excreted within 28-34 h.